Tempest Therapeutics, Inc. — Director's Dealing 2015

Oct 7, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OvaScience, Inc. (OVAS)
CIK: 0001544227
Period of Report: 2015-10-05

Reporting Person: Young Jeffrey E (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-10-05	Common Stock	P	3450	$10.70	Acquired	3750	Direct